FDA Submits Proposed Information Collection for Enhanced Review Transparency and Communication

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995, as part of its efforts to enhance review transparency and communication for new molecular entity new drug applications and original biologics license applications under the Prescription Drug User Fee Acts.